Ryu Eun Bi, Chang Jung Min, Seo Mirinae, Kim Sun Ah, Lim Ji He, Moon Woo Kyung
Department of Radiology, Dongnam Institute of Radiological and Medical Sciences Cancer Center, Busan, Korea.
Department of Radiology, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea.
Eur Radiol. 2014 Sep;24(9):2227-35. doi: 10.1007/s00330-014-3256-0. Epub 2014 Jun 4.
The aim of our study was to evaluate the tumour volume doubling time (TVDT) of molecular breast cancer subtypes by serial ultrasound (US).
Sixty-six patients (mean age, 50 years; range, 29-78 years) with invasive breast cancer underwent initial and follow-up breast US examinations (at least three months apart) with no intervention. TVDT was determined using the tumours' greatest dimensions in two orthogonal planes. The results were compared with clinical, imaging, and tumour variables and molecular subtypes (oestrogen receptor [ER]-positive, human epidermal growth factor receptor 2 [HER2]-positive, and triple negative) using a multiple linear regression analysis.
TVDT exhibited a wide range (46-825 days; median, 141 days) with an overall mean of 193 ± 141 days and mean values of 241 ± 166 days for ER-positive tumours (n = 37), 162 ± 60 days for HER2-positive tumours (n = 12), and 103 ± 43 days for triple-negative tumours (n = 17) (P < 0.0001). In a multivariate regression analysis, compared to other features, only the different molecular breast cancer subtypes showed significant difference in TVDT (P < 0.0001).
TVDT differed significantly among the three molecular breast cancer subtypes, with the triple-negative tumours showing the fastest growth.
Knowledge of tumour volume doubling time provides clues for improving screening. TVDT assessed by serial US differed significantly between breast cancer subtypes. Triple-negative tumours had 2.4-fold shorter TVDT compared to ER-positive tumours. Tumours classified as BI-RADS 3 had shorter TVDT than BI-RADS 4.
本研究旨在通过连续超声（US）评估分子型乳腺癌亚型的肿瘤体积倍增时间（TVDT）。
66例浸润性乳腺癌患者（平均年龄50岁；范围29 - 78岁）在未进行干预的情况下接受了初次及后续乳腺超声检查（间隔至少3个月）。使用肿瘤在两个相互垂直平面上的最大径来确定TVDT。采用多元线性回归分析将结果与临床、影像和肿瘤变量以及分子亚型（雌激素受体[ER]阳性、人表皮生长因子受体2[HER2]阳性和三阴性）进行比较。
TVDT范围较宽（46 - 825天；中位数141天），总体平均值为193±141天，ER阳性肿瘤（n = 37）的平均值为241±166天，HER2阳性肿瘤（n = 12）为162±60天，三阴性肿瘤（n = 17）为103±43天（P < 0.0001）。在多变量回归分析中，与其他特征相比，仅不同的分子型乳腺癌亚型在TVDT上显示出显著差异（P < 0.0001）。
三种分子型乳腺癌亚型的TVDT差异显著，三阴性肿瘤生长最快。
肿瘤体积倍增时间的知识为改进筛查提供线索。通过连续超声评估的TVDT在乳腺癌亚型之间差异显著。与ER阳性肿瘤相比，三阴性肿瘤的TVDT短2.4倍。分类为BI-RADS 3的肿瘤比BI-RADS 4的肿瘤TVDT短。
